A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)

by | Aug 19, 2025 | Clinical Trials | 0 comments

​ Conditions: Influenza A

Interventions: Biological: AZD4117; Biological: AZD5315; Other: Placebo

Sponsors: AstraZeneca; Biomedical Advanced Research and Development Authority; Joint Program Executive Office (JPEO) Chemical, Biological, Radiological, and Nuclear Defense (CBRND) Enabling Biotechnologies (EB)

Not yet recruiting Conditions: Influenza A
Interventions: Biological: AZD4117; Biological: AZD5315; Other: Placebo
Sponsors: AstraZeneca; Biomedical Advanced Research and Development Authority; Joint Program Executive Office (JPEO) Chemical, Biological, Radiological, and Nuclear Defense (CBRND) Enabling Biotechnologies (EB)
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *